AbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
This story was republished with permission from Crain’s Chicago and written by Katherine Davis. As pharmaceutical giant AbbVie (NYSE: ABBV) continues its search for a new blockbuster drug, the company has agreed to pay close to $2 billion for new …